Did One Tiny Tweak Just Solve Heart Disease?

In April 2024, the trial that was supposed to end heart disease at the source nearly ended in disaster. One of the initial patients to receive the world's first gene-editing infusion designed to permanently lower cholesterol was four days post-treatment when their platelets crashed and their liver enzymes spiked. They didn't have any symptoms — and within days, the lab values came back to normal.…